-
2023-509247-27-00
5
Neonatal respiratory distress.
Pain and discomfort
-
2024-513292-40-00
5
Multiple sclerosis
-
2024-514243-29-01
5
This is a prospective, French, multicenter, open-label, design, strati
-
2024-516052-17-01
10
Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
-
2024-516215-24-00
4
TAkayasu ARteritiS
-
2024-517285-41-00
5
Newly diagnosed prostate cancer with pelvic lymph nodes metastases
-
2024-518138-10-00
4
Patients with DMMR and/or MSI metastatic colorectal cancer
-
2025-522832-16-00
10
Severe trauma
-
2025-524297-42-00
5
CLTI defined as Rutherford category 4 or 5
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-504254-35-00
7
2023-06-20
Unresectable locally advanced or metastatic solid tumors:
• Clear cell
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-513475-41-00
5
2025-02-03
Multiple Sclerosis
-
2023-504554-35-00
5
2025-01-17
incisional hernia
-
2024-510981-18-00
5
2024-12-12
Multiple Myeloma
Multiple myeloma (MM) is a B cell malignancy and is o
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2024-514101-65-00
4
2023-12-21
Multiple Myeloma